BRIEF-Arrowhead files for regulatory clearance to initiate Phase 1/2A study of ARO-MMP7 for idiopathic pulmonary fibrosis

Reuters
17 Aug 2022

Aug 17 (Reuters) - Arrowhead Pharmaceuticals Inc :

* ARROWHEAD FILES FOR REGULATORY CLEARANCE TO INITIATE PHASE 1/2A STUDY OF ARO-MMP7 FOR IDIOPATHIC PULMONARY FIBROSIS

* ARROWHEAD PHARMACEUTICALS INC - PENDING CLEARANCE, ARROWHEAD INTENDS TO PROCEED WITH AROMMP7-1001, A PHASE 1/2A STUDY

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10